HighMark Wealth Management LLC Has $4.56 Million Stake in AnaptysBio, Inc. $ANAB

HighMark Wealth Management LLC reduced its position in AnaptysBio, Inc. (NASDAQ:ANAB) by 30.4% during the fourth quarter, Holdings Channel.com reports. The firm owned 94,050 shares of the biotechnology company’s stock after selling 41,000 shares during the quarter. AnaptysBio accounts for approximately 1.9% of HighMark Wealth Management LLC’s holdings, making the stock its 11th biggest position. HighMark Wealth Management LLC’s holdings in AnaptysBio were worth $4,560,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Larson Financial Group LLC raised its holdings in AnaptysBio by 54.6% during the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after buying an additional 473 shares during the last quarter. Bessemer Group Inc. grew its holdings in shares of AnaptysBio by 950.0% during the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 1,292 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,377 shares during the last quarter. Osaic Holdings Inc. raised its holdings in shares of AnaptysBio by 11,630.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 2,326 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of AnaptysBio by 24.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 263 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on ANAB shares. Wedbush lifted their price target on AnaptysBio from $60.00 to $75.00 and gave the company an “outperform” rating in a research note on Thursday, March 12th. Truist Financial raised AnaptysBio to a “hold” rating in a report on Wednesday, March 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of AnaptysBio in a research note on Wednesday, January 21st. UBS Group raised their target price on AnaptysBio from $60.00 to $76.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Barclays lifted their target price on AnaptysBio from $63.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $78.73.

AnaptysBio Stock Performance

AnaptysBio stock opened at $62.69 on Thursday. AnaptysBio, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $72.36. The firm’s 50-day simple moving average is $62.56 and its 200 day simple moving average is $51.42. The stock has a market cap of $1.82 billion, a PE ratio of -58.05 and a beta of 0.79.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($0.64) by ($1.20). AnaptysBio had a negative net margin of 11.53% and a negative return on equity of 1,101.24%. The firm had revenue of $25.56 million during the quarter, compared to analysts’ expectations of $18.86 million. As a group, analysts predict that AnaptysBio, Inc. will post -1.3 EPS for the current fiscal year.

AnaptysBio declared that its board has authorized a stock buyback plan on Friday, March 27th that authorizes the company to buyback $100,000.00 billion in shares. This buyback authorization authorizes the biotechnology company to reacquire up to 5,352,316.2% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In other AnaptysBio news, Director John P. Schmid sold 20,645 shares of the business’s stock in a transaction on Monday, March 30th. The stock was sold at an average price of $56.11, for a total value of $1,158,390.95. Following the transaction, the director owned 31,622 shares of the company’s stock, valued at approximately $1,774,310.42. The trade was a 39.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Faga sold 17,679 shares of the company’s stock in a transaction on Friday, March 27th. The shares were sold at an average price of $61.61, for a total value of $1,089,203.19. Following the completion of the transaction, the chief executive officer owned 495,965 shares of the company’s stock, valued at $30,556,403.65. This trade represents a 3.44% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 33.50% of the company’s stock.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.